Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Phase 2

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: LY3871801

First Posted Date: 2023-05-08

Last Posted Date: 2024-08-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 380

Registration Number: NCT05848258

Locations: 🇭🇺
CRU Hungary Kft., Encs, Borsod-Abaúj-Zemplén, Hungary
🇭🇺
Regia Med Kft, Szekesfehervar, Fejér, Hungary
🇭🇺
Revita Clinic, Budapest, Pest, Hungary

and more 59 locations

A Study of LY3819469 in Participants With Impaired and Normal Renal Function

Phase 1

Completed

Conditions: Healthy
Renal Insufficiency

Interventions: Drug: LY3819469

First Posted Date: 2023-05-03

Last Posted Date: 2024-03-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT05841277

Locations: 🇺🇸
Nucleus Networks, Saint Paul, Minnesota, United States
🇺🇸
Omega Research Consultants, Orlando, Florida, United States
🇺🇸
Floridian Clinical Research, Miami, Florida, United States

and more 1 locations

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Phase 1

Completed

Conditions: Healthy
Obese

Interventions: Drug: LY3502970

First Posted Date: 2023-05-03

Last Posted Date: 2024-10-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 52

Registration Number: NCT05841238

Locations: 🇺🇸
LabCorp CRU, Inc., Madison, Wisconsin, United States
🇺🇸
Labcorp Clinical Research LP, Dallas, Texas, United States

A Study of the Effect of Food on LY3537982 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3537982

First Posted Date: 2023-04-24

Last Posted Date: 2023-09-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT05824858

Locations: 🇺🇸
ICON, Salt Lake City, Utah, United States

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Phase 3

Completed

Conditions: Overweight
Obesity

Interventions: Drug: Tirzepatide
Drug: Semaglutide

First Posted Date: 2023-04-21

Last Posted Date: 2024-12-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 751

Registration Number: NCT05822830

Locations: 🇺🇸
Southern California Dermatology, Inc., Santa Ana, California, United States
🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

and more 29 locations

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tirzepatide
Device: Single Dose Pen
Device: Multi-use Prefilled Pen

First Posted Date: 2023-04-12

Last Posted Date: 2024-10-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 65

Registration Number: NCT05810597

Locations: 🇺🇸
ICON, Salt Lake City, Utah, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes
Obesity
Overweight or Obesity
Overweight
Cardiovascular Diseases
Chronic Kidney Disease

Interventions: Drug: Orforglipron
Drug: Insulin Glargine

First Posted Date: 2023-04-07

Last Posted Date: 2024-12-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2749

Registration Number: NCT05803421

Locations: 🇺🇸
The Research Center of The Upstate, Greenville, South Carolina, United States
🇺🇸
Care Access - Mauldin, Mauldin, South Carolina, United States
🇺🇸
New Phase Research and Development, Knoxville, Tennessee, United States

and more 373 locations

A Multiple-Dose Study of LY3493269 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3493269

First Posted Date: 2023-04-03

Last Posted Date: 2023-08-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 42

Registration Number: NCT05794243

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Mirikizumab IV
Drug: Mirikizumab SC

First Posted Date: 2023-03-24

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT05784246

Locations: 🇺🇸
Pediatric Gastroenterology Prisma Health - Upstate, Greenville, South Carolina, United States
🇺🇸
Rady Children's Hospital- San Diego, San Diego, California, United States
🇺🇸
University of California-San Francisco-Mission Bay, San Francisco, California, United States

and more 53 locations

A Study of LY3473329 in Participants With Impaired and Normal Renal Function

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: LY3473329

First Posted Date: 2023-03-21

Last Posted Date: 2024-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT05778864

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
🇺🇸
Velocity Clinical Research, New Smyrna Beach, Edgewater, Florida, United States
🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy